Molecules Targeting Colorectal Cancer Stem Cells

About RhemaStem

RhemaStem is a private, preclinical-stage biotech focused on a novel approach to treating solid cancers by targeting cancer stem cells (CSCs). Its core innovation is a proprietary culture medium and platform that enables the isolation and perpetual propagation of bona fide human colorectal cancer stem cells in vitro, a historically significant challenge. The company's pipeline includes small-molecule programs targeting colorectal CSCs and metastasis, as well as a stem cell therapy program for inflammatory bowel disease, positioning it at the intersection of advanced cell biology and oncology drug development.

Therapeutic Areas